Abstract
Skin and mucosal diseases can be the first manifestation of asymptomatic HIV infection, may indicate advancing immunodeficiency, or may represent systemic opportunistic infections or neoplasms. Mucocutaneous diseases are highly prevalent in the HIV-infected population and multiple pathologies are common particularly with advanced immunosuppression. The dominant HIV-associated skin diseases are infectious and inflammatory and they can cause significant morbidity. Although skin cancers are less common their prognosis is often worse. Clinical presentations are often atypical and may vary depending on the level of immunosuppression. Managing skin disease in the context of advanced immunosuppression is challenging and they often respond poorly to conventional therapies. This improves with the commencement of antiretrovirals (ARVs) and immune restoration. Despite the significant decline in HIV-related skin diseases with ARVs, the drugs themselves have brought with them a range of other skin-associated problems: adverse effects, an increased risk of drug reactions, and immune reconstitution-associated skin diseases. Therefore, the burden of skin disease remains high even in the era ARVs and the aim of this review is to equip physicians managing HIV-infected patients with knowledge of the spectrum of skin disorders associated with HIV-related immunosuppression.
Keywords: HIV, infection, skin, inflammatory, neoplasmas, antivirals
Current HIV Research
Title: Cutaneous Markers of HIV Infection and Progression
Volume: 8 Issue: 6
Author(s): Mahreen Ameen
Affiliation:
Keywords: HIV, infection, skin, inflammatory, neoplasmas, antivirals
Abstract: Skin and mucosal diseases can be the first manifestation of asymptomatic HIV infection, may indicate advancing immunodeficiency, or may represent systemic opportunistic infections or neoplasms. Mucocutaneous diseases are highly prevalent in the HIV-infected population and multiple pathologies are common particularly with advanced immunosuppression. The dominant HIV-associated skin diseases are infectious and inflammatory and they can cause significant morbidity. Although skin cancers are less common their prognosis is often worse. Clinical presentations are often atypical and may vary depending on the level of immunosuppression. Managing skin disease in the context of advanced immunosuppression is challenging and they often respond poorly to conventional therapies. This improves with the commencement of antiretrovirals (ARVs) and immune restoration. Despite the significant decline in HIV-related skin diseases with ARVs, the drugs themselves have brought with them a range of other skin-associated problems: adverse effects, an increased risk of drug reactions, and immune reconstitution-associated skin diseases. Therefore, the burden of skin disease remains high even in the era ARVs and the aim of this review is to equip physicians managing HIV-infected patients with knowledge of the spectrum of skin disorders associated with HIV-related immunosuppression.
Export Options
About this article
Cite this article as:
Ameen Mahreen, Cutaneous Markers of HIV Infection and Progression, Current HIV Research 2010; 8 (6) . https://dx.doi.org/10.2174/157016210793499349
DOI https://dx.doi.org/10.2174/157016210793499349 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PRAME/EZH2-Mediated Regulation of TRAIL: A New Target for Cancer Therapy
Current Molecular Medicine Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Novel Aglycones of Steroidal Glycoalkaloids as Potent Tyrosine Kinase Inhibitors: Role in VEGF and EGF Receptors Targeted Angiogenesis
Letters in Drug Design & Discovery The Functions of F-box Proteins in Regulating the Epithelial to Mesenchymal Transition
Current Pharmaceutical Design The Role of Major Histocompatibility Complex Polymorphisms in the Incidence and Outcome of Non-Hodgkin Lymphoma
Current Immunology Reviews (Discontinued) Role of the Non-Receptor Tyrosine Kinase Fes in Cancer
Current Medicinal Chemistry MDM4 (MDMX) and its Transcript Variants
Current Genomics Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Current Cancer Drug Targets Nanotherapeutics in Tumour Microenvironment for Cancer Therapy
Nanoscience & Nanotechnology-Asia The Vanilloid Agonist Resiniferatoxin for Interventional-Based Pain Control
Current Topics in Medicinal Chemistry Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets Herpes Simplex Viruses in Antiviral Drug Discovery
Current Pharmaceutical Design Role of Calcium, Vitamin D, and the Extrarenal Vitamin D Hydroxylases in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
Current Medicinal Chemistry Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
Current Pharmaceutical Design Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Thalidomide Analogues as Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Editorial
Recent Patents on Anti-Cancer Drug Discovery